植物疗法在缺血性中风中的进展,针对PI3K/Akt信号传导
Tianlong Liu1,2, Wenjun Wang3, Xiaolin Li1
1Department of Pharmacy, The 940th Hospital Joint Logistics Support Forces of PLA, Lanzhou, China.
Phytotherapy research : PTR
|August 29, 2023
概括
本综述探讨了用于治疗缺血性中风的天然化合物,这些化合物向酸氨基3-激酶/Akt (PI3K/Akt) 途径. 这些天然产品在缓解神经障碍方面表现有前途,提供新的治疗途径.
科学领域:
- 神经科学是一个神经科学.
- 药理学 药理学是指药理学的学科.
- 生物化学 生物化学
背景情况:
- 缺血性中风的发病过程很复杂,包括炎症,氧化应激,亡和内皮功能障碍.
- 酸丁3-酶/Akt (PI3K/Akt) 信号通路对于调节这些过程而言至关重要.
- 针对PI3K/Akt路径是开发新型抗胰岛素中风药物的关键重点.
研究的目的:
- 在过去二十年中,审查针对PI3K/Akt路径的抗胰岛素中风药物的研究.
- 探索天然化合物的治疗潜力,以减轻由缺血性中风引起的神经系统缺陷.
- 总结当前的研究,确定局限性,并建议PI3K/Akt途径基于中风治疗的未来方向.
主要方法:
- 系统审查关于PI3K/Akt途径抑制剂用于缺血性中风的科学文献.
- 对研究天然产品 (黄类,类,类等) 的研究进行分析. 对于神经保护作用.
- 对东亚传统医疗实践的评估,以深入了解中风治疗.
主要成果:
- 来自各种来源的众多天然化合物已证明在缓解与缺血性中风相关的神经功能障碍方面具有有效性.
- 草本提取物和传统配方显示出显著的治疗潜力,由几个世纪的临床使用支持.
- PI3K/Akt路径是一个经过验证的目标,天然产品提供了有希望的候选药物来源.
结论:
- 自然产品是开发针对PI3K/Akt途径的新型抗缺血性中风疗法的宝贵资源.
- 将传统知识与现代研究相结合,可以加速发现有效的中风治疗方法.
- 需要进一步的研究来优化基于天然化合物的疗法,并克服缺血性中风治疗当前的挑战.
相关概念视频
01:22PI3K/mTOR/AKT Signaling Pathway
3.6K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
3.6K
01:27Peripheral Artery Disease III: Interprofessional Care
11
Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
11
01:26Atherosclerosis III: Management
12
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
12
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
560
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
560
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
213
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
213